Few recent ASX listings have divided opinion as sharply as Saluda Medical (ASX:SLD), the Australian-founded, Minnesota-headquartered maker of the Evoke closed-loop spinal cord stimulation system for chronic pain. After raising roughly A$231 million in a December 2025 float priced at A$2.65 per CHESS Depositary Interest, the stock tumbled on debut and has traded well below its issue price since. Yet the operating numbers released in late July 2026 tell a story of accelerating commercial traction in a large and stubbornly underserved market.

Originally incorporated in Australia in 2010 and now run from Bloomington, Minnesota under chief executive Barry Regan, Saluda has retained a distinctly Australian shareholder register and board while building the bulk of its business in the United States. For a company still burning cash to build scale, the investment case hinges on whether its differentiated technology can convert clinical evidence into durable market share against three of the world's largest device makers.

Revenue beats guidance as US momentum builds

In its maiden full-year result as a listed company, Saluda reported FY26 revenue of US$90.2 million, comfortably ahead of its US$87 million guidance and up from US$70.4 million in FY25. Fourth-quarter revenue reached US$27.0 million, a 43 per cent lift on the prior corresponding period, with US sales of US$18.4 million (up 45 per cent) and international revenue of US$8.5 million (up 39 per cent). Management reported 769 patient implantations in the quarter, a 50 per cent year-on-year increase.

The company finished the year with US$116.4 million in cash and roughly US$141 million of total available funding after drawing on a debt facility. Its US sales force had grown to 161 representatives by 30 June 2026, from an average of about 89 fully trained representatives across the year, and both the number of active implanting physicians and the utilisation per physician rose more than 20 per cent in the fourth quarter. Even so, Saluda estimates it has penetrated only about 4 per cent of its addressable base of implanting physicians, a figure it frames as evidence of a long runway rather than a mature franchise.

A large market with a persistent unmet need

Chronic pain is one of medicine's most intractable problems, and spinal cord stimulation (SCS) has become an established option when drugs and surgery fail. Grand View Research valued the global SCS device market at about US$2.7 billion in 2023 and projects it reaching roughly US$4.7 billion by 2030 at a compound annual growth rate near 8 per cent. The field has long been dominated by Medtronic, Abbott and Boston Scientific alongside pure-play Nevro. Saluda's pitch is that most conventional systems deliver fixed, open-loop stimulation that patients must repeatedly have adjusted.

The Evoke platform instead measures the spinal cord's own electrical response, the evoked compound action potential or ECAP, and adjusts each stimulation pulse in real time to hold neural activation at a target level. Saluda points to its long-term clinical data, reporting that 83 per cent of patients achieved at least a 50 per cent reduction in pain at 36 months, that 55 per cent reduced or eliminated opioid use, and that patients required fewer than one reprogramming visit a year versus about six for standard devices. These are company-reported outcomes drawn from its Evoke clinical program rather than independent verification, but they underpin the closed-loop differentiation and dovetail with mounting pressure on clinicians to reduce opioid reliance.

Catalysts building for ASX:SLD

Several near-term drivers could support the growth narrative. In July 2026 Saluda performed its first US surgeries using the newly FDA-approved CAP24 surgical paddle lead, opening a segment that accounts for roughly 30 per cent of US SCS implants and was previously beyond Evoke's reach. The company also secured European regulatory approval for its EVA sensing technology, with recognition in Australia, extending a physiologic-sensing roadmap that management sees as widening the moat around the Evoke platform.

Beyond product approvals, the key operating levers are sales-force productivity and physician adoption. With average trained representative numbers still ramping through FY26 and utilisation per physician rising, incremental gains in either metric flow quickly to revenue. Management has guided to continued strong growth, though investors should treat forward targets as management expectations rather than commitments.

The risks: heavyweight rivals and a cash-hungry model

The risks are material. Saluda is competing against Medtronic, Abbott, Boston Scientific and Nevro, companies with vastly greater balance sheets, entrenched hospital relationships and their own closed-loop and sensing programs. Any competitive response on price, features or reimbursement could blunt Saluda's momentum. Reimbursement itself is a perennial variable in the United States, where coverage decisions and coding shifts can materially affect device economics.

The company also remains loss-making and is spending heavily to scale, meaning execution risk is high; a stumble in hiring, training or physician conversion would quickly show up in the numbers. While the year-end cash balance provides a buffer, sustained investment could require further capital, and the share price has stayed well below the December 2025 issue price, reflecting investor caution about the path to profitability.

A balanced read on ASX:SLD

Saluda Medical (ASX:SLD) offers a genuinely differentiated technology addressing a large, underserved market, and its FY26 result shows a commercial engine gaining speed and beating its own guidance. The CAP24 paddle-lead approval and expanding sensing portfolio add plausible catalysts. Against that, the company must prove it can keep taking share from far larger, well-capitalised incumbents while funding heavy growth investment and navigating US reimbursement.

For now, the operating trajectory and the technology story are encouraging, but the risks around competition, cash burn and execution remain real. Investors will be watching whether accelerating revenue can, over time, narrow the gap between Saluda's clinical promise and its market valuation.